Page 7,103«..1020..7,1027,1037,1047,105..7,1107,120..»

Adult Stem Cell Treatments for COPD -Real patient results, USA Stem Cells- Shirlen M. Testimonial – Video

Posted: Published on February 21st, 2012

11-01-2012 23:04 If you would like more information please call us Toll Free at 877-578-7908. Or visit our website at http://www.usastemcells.com Or click here to have a Free Phone Constultation with Dr. Matthew Burks usastemcells.com Real patient testimonials for USA Stem Cells. Adult stem cell therapy for COPD, Emphysema, and Pulmonary fibrosis. Read the original post: Adult Stem Cell Treatments for COPD -Real patient results, USA Stem Cells- Shirlen M. Testimonial - Video … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on Adult Stem Cell Treatments for COPD -Real patient results, USA Stem Cells- Shirlen M. Testimonial – Video

medi-post.wmv – Video

Posted: Published on February 21st, 2012

28-01-2012 00:47 Care for Patients, Innovations from Research" Making better quality living within reach MEDIPOST is a leading stem cell biotechnology company focused on developing products to meet unmet medical needs such as those related to regenerative or functional recovery of knee articular cartilage, the nervous system, the pulmonary system and hematopoietic transplantation engraftment areas. Revolutionizing medical care MEDIPOST provides services and develops products related to a readily available and non-controversial source - human umbilical cord blood and human Umbilical Cord Blood derived Mesenchymal Stem Cells (hUCB-MSCs), respectively. The stem cells, coming from unrelated healthy donors, have demonstrated the ability to regenerate and/or to recover functionality of different types of damaged tissues. Such adult stem cell therapies having an "off-the-shelf" concept revolutionize medical treatments and are bringing about a new era of mass-manufactured allogeneic stem cell drug products. Read the rest here: medi-post.wmv - Video … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on medi-post.wmv – Video

Ligand Licenses DARA Program to Retrophin

Posted: Published on February 21st, 2012

SAN DIEGO & NEW YORK--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND - News) and Retrophin, LLC announced that the companies have entered into an agreement in which Ligand has licensed rights to DARA (a Dual Acting Receptor Antagonist of Angiotensin and Endothelin receptors) to Retrophin. Under the terms of the agreement, Ligand will receive a net upfront payment of $1 million, and may receive, net of amounts owed to third parties, over $75 million in milestone payments based on clinical and regulatory progress as well as 9% in royalties on potential future worldwide sales by Retrophin. “DARA has the promise to be a significant medicine, and we are excited to partner with Retrophin to advance the development of the program and bring it closer to patients in need,” said John Higgins, President and Chief Executive Officer of Ligand Pharmaceuticals. “This is an attractive deal for Ligand and our shareholders. We have partnered DARA with a team that has great credentials, is highly motivated to advance the program and has a compelling development plan. This is another valuable asset in our late-stage portfolio.” Retrophin intends to develop DARA for orphan indications of severe kidney diseases including Focal Segmental Glomerulosclerosis (FSGS) as well as conduct proof-of-concept studies … Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Ligand Licenses DARA Program to Retrophin

Cure Duchenne Announces Three New Funded Research Projects to Help Develop Treatments and Find a Cure for Duchenne …

Posted: Published on February 21st, 2012

Newport Beach, Calif., Feb. 21, 2012 (GLOBE NEWSWIRE) -- CureDuchenne, a nonprofit organization that raises awareness and funds multiple research and development projects to cure Duchenne muscular dystrophy, announces the funding of three new research projects following its third annual CureDuchenne Scientific Summit. CureDuchenne is dedicated to finding treatments and a cure for Duchenne regardless of the specific genetic mutation by advancing drug development programs, identifying new drug targets that exhibit potential to transform the treatment of Duchenne and help drive the most promising research programs to market. CureDuchenne's comprehensive research portfolio now funds three new projects that includes development of a new MDX mouse model with duplicated exons, a study with currently approved drugs that may help treat critical cardiac issues and also supports the reformulation of the utrophin upregulator SMT C1100. "CureDuchenne takes a comprehensive and strategic approach to the projects we fund," said Debra Miller, founder and CEO of CureDuchenne. "Every Duchenne child is important so we are funding three promising research projects that address a variety of mutations and could lead to better treatments and hope for Duchenne families." MDX Mouse Model There is currently no animal model with a Duchenne muscular dystrophy duplication and this … Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Cure Duchenne Announces Three New Funded Research Projects to Help Develop Treatments and Find a Cure for Duchenne …

Parent Project Muscular Dystrophy Awards $500,000 to Tivorsan Pharmaceuticals

Posted: Published on February 21st, 2012

To: HEALTH, MEDICAL AND NATIONAL EDITORS Grant Funds Work of Tivorsan Pharmaceuticals' Team to Bring Recombinant Biglycan to the Clinic for the Possible Treatment of Duchenne Muscular Dystrophy HACKENSACK, N.J., Feb. 21, 2012 /PRNewswire-USNewswire/ -- Parent Project Muscular Dystrophy (PPMD) announced today that it will award Tivorsan Pharmaceuticals (Tivorsan) a $500,000 grant to develop the company's biglycan therapeutic candidate for Duchenne muscular dystrophy. (Logo: http://photos.prnewswire.com/prnh/20100119/DC39975LOGO) Dr. Justin Fallon of Brown University, the founding scientist of Tivorsan, was the recipient of PPMD's first End Duchenne Grant in 2008. Building on that work, the Tivorsan team seeks to use recombinant human biglycan (rh-BGN) to increase utrophin at the muscle cell membrane, resulting in reduced muscle damage and improved function. Utrophin is a molecule that is related to dystrophin in structure and form and can "stand in" for dystrophin when present in greater than normal quantities. Biglycan is a naturally occurring protein made up of amino acids and carbohydrate chains that is found in large amounts on the outside of developing and regenerating muscle cells. The form of biglycan that is active therapeutically contains only simple carbohydrate side chains. For this reason, rh-BGN is straightforward to manufacture. PPMD President and CEO Pat Furlong … Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Parent Project Muscular Dystrophy Awards $500,000 to Tivorsan Pharmaceuticals

Promising New Epilepsy Therapies Featured at 2012 Epilepsy Pipeline Update Conference

Posted: Published on February 21st, 2012

To: HEALTH, MEDICAL AND NATIONAL EDITORS Epilepsy Therapy Project Announces "Shark Tank" Winner with Most Innovative Product WASHINGTON, Feb. 21, 2012 /PRNewswire-USNewswire/ -- The Epilepsy Therapy Project (ETP), a non-profit organization whose mission is to accelerate new therapies for people living with epilepsy and seizures, and the parent organization of epilepsy.com, today released presentation highlights from its successful 2012 Epilepsy Pipeline Update Conference held in San Francisco and announced the winner of its "Shark Tank" competition for the most innovative new product idea in epilepsy treatment and care. This year's epilepsy pipeline conference featured a stellar line up of leading drug and device developers, investigators and industry leaders and showcased cutting-edge epilepsy therapies in development, including medical technology and therapeutic products. The winner of ETP's inaugural "Shark Tank" competition is Charles Anderson of HiPass Design for his Smartphone-based Movement Detector, a life-saving seizure alarm. Anderson's invention was inspired from a personal concern that he was unable to detect his son's seizures at night. Anderson first devised a computer system that analyzed images from an infrared camera and detected seizure movements with few false alarms. The prototype system, which incorporates an iPhone with camera, sounds an alarm while recording valuable video … Continue reading

Comments Off on Promising New Epilepsy Therapies Featured at 2012 Epilepsy Pipeline Update Conference

Treating Autism With Antibiotics (France 3 19/20, Feb 17, 2012) – Video

Posted: Published on February 21st, 2012

20-02-2012 08:59 A news report on France 3 (a public channel of French television) about the successful treatment of autistic children with antibiotics. Read the original here: Treating Autism With Antibiotics (France 3 19/20, Feb 17, 2012) - Video … Continue reading

Comments Off on Treating Autism With Antibiotics (France 3 19/20, Feb 17, 2012) – Video

Gaylord Hotels Helps Spread the Word about Autism Speaks

Posted: Published on February 21st, 2012

Rooms for Good program to raise funds for the world’s leading autism and science advocacy organization in March and April Nashville, TN (PRWEB) February 21, 2012 Gaylord Hotels knows what it means to give voice to a good cause. The hotel group has been working to support charities through its Rooms for Good program for the last year, and today announced Autism Speaks as its March/April partner. Gaylord hotels will donate 10 percent of proceeds raised through a special package rate available at all four Gaylord Hotels resorts throughout March and April to Autism Speaks. “Gaylord Hotels’ Rooms for Good program has allowed us to help some wonderful organizations,” said Amy A. Atkinson, vice president of marketing and public relations, Gaylord Hotels, “and we are very appreciative of this opportunity to lend another voice to the Autism Speaks campaign. We are excited to be able to work with them again this year to help raise awareness and funds.” The world’s leading autism science and advocacy organization, Autism Speaks works to change the future for all who struggle with autism spectrum disorders by funding biomedical research into the causes, prevention, and treatments; raising public awareness about autism and its effects on … Continue reading

Comments Off on Gaylord Hotels Helps Spread the Word about Autism Speaks

Autism expert Temple Grandin to discuss building youngsters’ talents at Toronto seminar

Posted: Published on February 21st, 2012

February 20, 2012 Comments on this story (0) Barbara Turnbull LIFE REPORTER Meaningful work for people with autism and Asperger’s syndrome is possible when abilities are nurtured from a young age, says autism advocate Temple Grandin. That’s a message Grandin will bring to Toronto on Tuesday, as part of a seminar on developing talents for young adults with autism, a complex neurobiological disorder that impairs a person’s ability to communicate and relate to others, and Asperger’s, a milder form of the disorder. Grandin, 64, is best known for her revolutionary transformation of livestock-handling facilities and her best-selling books The Way I See It and Thinking in Pictures about how people with autism think. She earned a PhD in animal science from the University of Illinois and is now an associate professor at Colorado State University. She was already in demand as a public speaker when her profile exploded in 2010 with HBO’s Emmy Award-winning movie Temple Grandin, starring Claire Danes. That same year, she was named one of Time magazine’s 100 most influential people. She doesn’t get home much these days, she says in a recent telephone interview from Sacramento, Calif., and enjoys sharing her messages with appreciative audiences. Here … Continue reading

Comments Off on Autism expert Temple Grandin to discuss building youngsters’ talents at Toronto seminar

Autism Diagnosis Often Occurs Later for Black Children

Posted: Published on February 21st, 2012

MONDAY, Feb. 20 (HealthDay News) -- Black children with autism tend to be diagnosed later than white children with the disorder, and this delay can lead to longer and more intensive treatment, researchers say. Lack of access to quality, affordable and culturally knowledgeable health care are among the reasons for the delay in a diagnosis of autism in black children, said researcher Martell Teasley, an associate professor in the College of Social Work at Florida State University in Tallahassee. Teasley also suggested that social stigma attached to mental health issues within the black community may add to the problem. Some black parents may find it hard to accept that their child has autism, so even when the disorder is diagnosed, there may be a reluctance to use autism treatment services. Misdiagnosis is also a potential problem, the study authors noted. "There are no subjective criteria for diagnosing autism. Only brain scans can truly provide appropriate diagnoses, because we are dealing with biological and chemical imbalances in the brain," Teasley said in a university news release. "Not every child is going to have access to this kind of medical evaluation, particularly those who are indigent and don't have health care funding." … Continue reading

Comments Off on Autism Diagnosis Often Occurs Later for Black Children

Page 7,103«..1020..7,1027,1037,1047,105..7,1107,120..»